Estimating the burden of adult hospitalized RSV infection including special populations.

[1]  G. Balasubramani,et al.  Estimating the burden of adult hospitalized RSV infection using local and state data - methodology , 2022, Human vaccines & immunotherapeutics.

[2]  Ya Gao,et al.  Global burden of upper respiratory infections in 204 countries and territories, from 1990 to 2019 , 2021, EClinicalMedicine.

[3]  S. Varga,et al.  Considerations for a Respiratory Syncytial Virus Vaccine Targeting an Elderly Population , 2021, Vaccines.

[4]  L. Saiman,et al.  Comparative incidence and burden of respiratory viruses associated with hospitalization in adults in New York City , 2020, Influenza and other respiratory viruses.

[5]  C. Amand,et al.  Incidence of respiratory syncytial virus related health care utilization in the United States , 2020, Journal of global health.

[6]  Q. S. Huang,et al.  Respiratory syncytial virus associated hospitalizations among adults with chronic medical conditions. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  Q. S. Huang,et al.  The health and economic burden of respiratory syncytial virus associated hospitalizations in adults , 2020, PloS one.

[8]  A. Glatman-Freedman,et al.  Respiratory Syncytial Virus hospitalizations burden: a nation-wide population-based analysis, 2000-2017. , 2020, The Journal of infection.

[9]  D. Swerdlow,et al.  The burden of respiratory syncytial virus in adults: a systematic review and meta-analysis , 2020, Epidemiology and Infection.

[10]  B. Scarpellini,et al.  Systematic review on respiratory syncytial virus epidemiology in adults and the elderly in Latin America , 2019, International Journal of Infectious Diseases.

[11]  M. Ison,et al.  Epidemiology and outcomes of hospitalized adults with respiratory syncytial virus: A 6‐year retrospective study , 2019, Influenza and other respiratory viruses.

[12]  A. Glatman-Freedman,et al.  Respiratory Syncytial Virus Hospitalization During Pregnancy in 4 High-income Countries, 2010–2016 , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  J. Stoddard,et al.  The epidemiology of medically attended respiratory syncytial virus in older adults in the United States: A systematic review , 2017, PloS one.

[14]  Robert J. Taylor,et al.  Estimates of hospitalization attributable to influenza and RSV in the US during 1997–2009, by age and risk status , 2017, BMC Public Health.

[15]  S. Pastula,et al.  Hospitalizations for Respiratory Syncytial Virus Among Adults in the United States, 1997–2012 , 2017, Open forum infectious diseases.

[16]  R. Harpaz,et al.  Prevalence of Immunosuppression Among US Adults, 2013. , 2016, JAMA.

[17]  V. Arora,et al.  The Challenge of Understanding Health Care Costs and Charges. , 2015, AMA journal of ethics.

[18]  Robert J. Taylor,et al.  Modelling estimates of the burden of Respiratory Syncytial virus infection in adults and the elderly in the United Kingdom , 2015, BMC Infectious Diseases.

[19]  T. Mazzulli,et al.  Respiratory syncytial virus infection-associated hospitalization in adults: a retrospective cohort study , 2014, BMC Infectious Diseases.

[20]  Yuwei Zhu,et al.  Respiratory syncytial virus- and human metapneumovirus-associated emergency department and hospital burden in adults , 2014, Influenza and other respiratory viruses.

[21]  K. Edwards,et al.  Rates of hospitalizations for respiratory syncytial virus, human metapneumovirus, and influenza virus in older adults. , 2012, The Journal of infectious diseases.

[22]  D. Fleming,et al.  Morbidity profiles of patients consulting during influenza and respiratory syncytial virus active periods , 2007, Epidemiology and Infection.

[23]  E. Walsh,et al.  Respiratory syncytial virus infection in elderly and high-risk adults. , 2005, The New England journal of medicine.

[24]  R. Karron,et al.  Respiratory Syncytial Virus Vaccines , 1998, Clinical Microbiology Reviews.